3 Health Services Stocks Pushing The Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 67 points (-0.4%) at 17,031 as of Tuesday, Sept. 2, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,211 issues advancing vs. 1,801 declining with 159 unchanged.

The Health Services industry currently sits down 0.1% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include Edwards Lifesciences ( EW), down 2.1%, Humana ( HUM), down 1.3%, Grifols ( GRFS), down 1.0%, Boston Scientific ( BSX), down 0.7% and Stryker Corporation ( SYK), down 0.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Catamaran ( CTRX) is one of the companies pushing the Health Services industry higher today. As of noon trading, Catamaran is up $0.45 (1.0%) to $47.57 on average volume. Thus far, 502,404 shares of Catamaran exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $47.09-$47.60 after having opened the day at $47.30 as compared to the previous trading day's close of $47.12.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Catamaran Corporation provides pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefits management industry in North America. The company operates in two segments: PBM and HCIT. Catamaran has a market cap of $9.8 billion and is part of the health care sector. Shares are down 0.7% year-to-date as of the close of trading on Friday. Currently there are 13 analysts who rate Catamaran a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Catamaran as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, increase in net income and notable return on equity. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Catamaran Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Agilent Technologies ( A) is up $0.51 (0.9%) to $57.67 on average volume. Thus far, 828,833 shares of Agilent Technologies exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $57.23-$57.96 after having opened the day at $57.23 as compared to the previous trading day's close of $57.16.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Agilent Technologies, Inc. provides bio-analytical and electronic measurement solutions and services to the life sciences, chemical analysis, diagnostics and genomics, communications, and electronics industries worldwide. Agilent Technologies has a market cap of $19.0 billion and is part of the health care sector. Shares are down 0.1% year-to-date as of the close of trading on Friday. Currently there are 8 analysts who rate Agilent Technologies a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Agilent Technologies as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Agilent Technologies Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Thermo Fisher Scientific ( TMO) is up $1.56 (1.3%) to $121.77 on average volume. Thus far, 1.1 million shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $120.57-$122.57 after having opened the day at $120.89 as compared to the previous trading day's close of $120.21.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics in the United States and internationally. Thermo Fisher Scientific has a market cap of $48.0 billion and is part of the health care sector. Shares are up 8.0% year-to-date as of the close of trading on Friday. Currently there are 13 analysts who rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, increase in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Thermo Fisher Scientific Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Netflix Shares Hit All-Time High as Market Flounders

Netflix Shares Hit All-Time High as Market Flounders

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Dow Tumbles as Trump Ratchets Up China Trade Fight

Dow Tumbles as Trump Ratchets Up China Trade Fight

Snap Shares Plunge After Cowen Cuts Price Target

Snap Shares Plunge After Cowen Cuts Price Target

FANG Stocks Get Swept Up in Broader Market Selloff

FANG Stocks Get Swept Up in Broader Market Selloff